ArticleHereditas2026
Whole blood miRNA expression signatures as predictors of neoadjuvant chemotherapy response in triple-negative breast cancer.
Article in Hereditas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTriple negative breast cancer (TNBC) is an aggressive malignancy distinguished by resistance to standard breast cancer therapies. The absence of reliable prognostic tools hinders the ability to predict therapeutic response, resulting in some patients receiving treatment that is ineffective yet physically exhausting. miRNAs are small non-coding RNA molecules that regulate gene expression, and their dysregulated profiles in liquid biopsies hold immense potential as minimally invasive biomarkers for monitoring treatment response.
resultsIn this study, we seek to identify miRNAs that may serve as predictive biomarkers for therapeutic responses in patients diagnosed with triple-negative breast cancer. To achieve this, an in silico analysis of the Cancer Genome Atlas (TCGA) dataset is conducted to narrow the list of candidate miRNAs. miRNAs with potential involvement in TNBC were selected for clinical validation in whole-blood samples of TNBC patients before and after therapy. The RT-qPCR-based expression analysis revealed significant predictive potential of miR-340-5p, miR-1307-3p, miR-185-5p, and miR-30a-3p.
conclusionsOur study identified that dysregulated miRNA signatures can serve as independent indicators for therapeutic monitoring. Notably, the combined multi-miRNA expression panel offers a robust, superior predictive value for stratifying treatment response and tracking disease progression in TNBC patients.
Indexed as
Identifiers
42421142What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.